Join to access to all OVN content. Join for Free
My Company has been sold, now what?!?”
pharmaceutical acquisitions corporate development biotech innovation market volatility economic downturn strategies

My Company has been sold, now what?!?”


Share This Article


Summary

In this episode, Tom Caravela welcomes Steve St. Onge to discuss the intricacies of corporate acquisitions within the pharmaceutical industry. Steve shares his journey through corporate development and provides insight into the transition and management of acquisitions, both before and after announcements. The conversation delves into the emotional and strategic aspects of navigating acquisitions, identifying warning signs, and the impact of market volatility. Steve offers practical advice for decision-making during economic downturns and strategies for embracing change and new opportunities in the pharma sector. The episode concludes with a discussion on future innovation and optimism in biotech, along with closing remarks and gratitude to listeners.

Steve St. Onge, Sr Director Business Development and Corporate Communications at Paratek discusses what to expect after your company has been acquired.

Steve shares….

👉 What to expect when acquisition news hits
👉 How to handle emotions and not panic
👉 What steps you should take after acquisition news
👉 What are the warning signs to be aware of
👉 Why is the pharma / biotech sector so volatile these days

Click for Source
pharmaceutical acquisitions, corporate development, biotech innovation, market volatility, economic downturn strategies

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Article
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
OVN Avatar Forbes Books Press Release Official

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Explore OVN